Calibrate Honored by Goldman Sachs for Entrepreneurship

Isabelle Kenyon, Founder & CEO, Calibrate Among the Most Exceptional Entrepreneurs at 2022 Builders and Innovators Summit

NEW YORK--(BUSINESS WIRE)--Goldman Sachs (NYSE:GS) recognized Isabelle Kenyon, Founder & CEO of Calibrate, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California.

Kenyon founded Calibrate in 2020 with a mission to change the way the world treats weight. As the first doctor-guided metabolic health company, Calibrate is setting the standard for treating obesity with a digital program that combines medication with behavior change to improve metabolic health and deliver long-term, sustainable results. Calibrate is the first and only outcomes-based model in obesity treatment and the first program with a guarantee backed by clinically-reviewed results data, helping its members achieve, and maintain, their metabolic health goals.

“Our vision is to put you in control of your health, and as the first doctor-guided metabolic health program of its kind, we’ve helped thousands of members to achieve their health goals,” said Kenyon. “Calibrate is changing the way the world treats weight by bringing decades of proven metabolic science to everyone, everywhere.”

“We were delighted to recognize Isabelle Kenyon as one of the most exceptional entrepreneurs of 2022,” said David M. Solomon, Chairman and CEO of Goldman Sachs. “They have made extraordinary contributions to a wide range of fields, and all of us were looking forward to meeting with these innovative thinkers.”

In addition to honoring the most exceptional entrepreneurs, the Summit consisted of general sessions and clinics led by seasoned entrepreneurs, academics, and business leaders as well as resident scholars.

About Calibrate

Calibrate is on a mission to change the way the world treats weight. As the first outcomes-based model in obesity treatment, Calibrate is setting the standard of care with a digital program that combines medication with behavior change to improve overall metabolic health, allowing people to sustain long-term weight loss results after medication. Calibrate is the first and only program to guarantee results backed by clinically reviewed data.

Recognized as a World Economic Forum Technology Pioneer and by Fast Company’s World Changing Ideas, the Employer Health Innovation Roundtable Traction Award Winner, and Goldman Sachs Builders & Innovators in 2022, Calibrate has raised $127.6M in cumulative funding from leading healthcare and consumer investors, including Founders Fund, Tiger Global, Threshold Ventures, Forerunner Ventures, Optum Ventures, and Redesign Health.